MedTrace Logo

ORKA-001 in Healthy Volunteers

NCT06698939 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-01

No results posted yet for this study

Summary

This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ORKA-001

ORKA-001 is supplied as sterile solution to be administered by SC injection

OTHER

Placebo

Placebo solution to be administered at a matching volume by SC injection

Sponsors & Collaborators

  • Oruka Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Kyle Breitschwerdt · Oruka Therapeutics, Inc.

  • Principal Investigator · Oruka Therapeutics Investigative Site

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-19
Primary Completion
2026-03-13
Completion
2026-03-13

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06698939 on ClinicalTrials.gov